For example, in 2001, SAGE was used to first demonstrate that mesothelin [34] and prostate stem cell antigen (PSCA) [35] were overexpressed in pancreatic adenocarcinoma. This evidence concerns the gene MSLN and pancreatic adenocarcinoma.